Literature DB >> 15680901

Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3.

Piotr Laidler1, Joanna Dulińska, Małgorzata Lekka, Janusz Lekki.   

Abstract

During the progression of prostate cancer from androgen-dependence or sensitivity to androgen-independence, the overall expression of prostate specific membrane antigen (PSMA) increases with its appearance in plasma membrane. However, surprisingly some androgen-independent metastatic prostate cancer cell lines do not express this protein. Estradiol (E2) and basic fibroblast growth factor (bFGF) due to their recognized and strong involvement in prostate growth, development, and pathology were selected with the aim of restoring the expression of PSMA in markedly dedifferentiated prostate cancer PC-3 cells and in Du 145. E2 (10(-7)-10(-11)M) and bFGF (10ng/ml) stimulated the expression of mRNAs for PSMA (2- to 4-fold increase) that apparently were further translated and processed to its membrane form in LNCaP, PC-3, and Du 145 cells. The values of interaction force between the same anti-PSMA antibodies and all studied cells were almost identical (45-64pN), indicating antigenic similarity of the membrane form of PSMA expressed in LNCaP, PC-3, and Du 145 cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15680901     DOI: 10.1016/j.abb.2004.12.003

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  20 in total

Review 1.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

3.  Novel Gastrin-Releasing Peptide Receptor Targeted Near-Infrared Fluorescence Dye for Image-Guided Surgery of Prostate Cancer.

Authors:  Amerigo Pagoto; Francesca Garello; Giada Maria Marini; Martina Tripepi; Francesca Arena; Paola Bardini; Rachele Stefania; Stefania Lanzardo; Giovanni Valbusa; Francesco Porpiglia; Matteo Manfredi; Silvio Aime; Enzo Terreno
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

4.  Prostate cancer targeting motifs: expression of αν β3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts.

Authors:  Robert M Taylor; Virginia Severns; David C Brown; Marco Bisoffi; Laurel O Sillerud
Journal:  Prostate       Date:  2011-07-11       Impact factor: 4.104

Review 5.  Prostate-specific membrane antigen-based imaging.

Authors:  Joseph R Osborne; Naveed H Akhtar; Shankar Vallabhajosula; Alok Anand; Kofi Deh; Scott T Tagawa
Journal:  Urol Oncol       Date:  2012-05-31       Impact factor: 3.498

6.  Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use.

Authors:  Tingting He; Mengzhe Wang; Hui Wang; Hongpei Tan; Yongxiang Tang; Eric Smith; Zhanhong Wu; Weihua Liao; Shuo Hu; Zibo Li
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-01       Impact factor: 9.236

7.  The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells.

Authors:  Awatef Ben Jemaa; Sataa Sallami; Dunia Ramarli; Marco Colombatti; Ridha Oueslati
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

8.  Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells.

Authors:  Mikhail G Dozmorov; Robert E Hurst; Daniel J Culkin; Bradley P Kropp; Mark Barton Frank; Jeanette Osban; Trevor M Penning; Hsueh-Kung Lin
Journal:  Prostate       Date:  2009-07-01       Impact factor: 4.104

9.  Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.

Authors:  Chunsheng Liu; Kosei Hasegawa; Stephen J Russell; Michel Sadelain; Kah-Whye Peng
Journal:  Prostate       Date:  2009-07-01       Impact factor: 4.104

Review 10.  177Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements.

Authors:  Jianpeng Cao; Yue Chen; Mei Hu; Wei Zhang
Journal:  Ann Nucl Med       Date:  2021-06-27       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.